Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| GNPX | 8-K | neutral | 2/10 | Genprex issued a press release highlighting peer-reviewed mouse research on the TUSC2 tumor suppressor gene's role in br | Oct 21, 2026 |
| VVOS | 8-K | neutral | 4/10 | Vivos Therapeutics received a letter from Nasdaq on October 20, 2026 confirming compliance with the minimum stockholders | Oct 21, 2026 |
| PDSB | 8-K | neutral | 4/10 | PDS Biotechnology filed an updated corporate presentation deck on October 20, 2026, highlighting clinical data for its t | Oct 20, 2026 |
| MTEX | 8-K | bearish | 6/10 | Mannatech dismissed BDO USA as its independent auditor and engaged CBIZ CPAs, effective October 15, 2026. The filing not | Oct 20, 2026 |
| ASBP | 8-K/A | mixed | 7/10 | Aspire-Lakewood Holdings, Inc. (ASBP) acquired Dura Driver Control Systems (DCS) for approximately $30 million in cash o | Oct 20, 2026 |
| LNZA | 8-K | mixed | 6/10 | LanzaTech Global completed a recapitalization and deleveraging of its subsidiary LanzaJet, including a $10M senior secur | Oct 20, 2026 |
| SRZN | 8-K | bullish | 6/10 | Surrozen closed the second and final tranche of its March 2025 private placement, raising ~$95.1M in gross proceeds foll | Oct 20, 2026 |
| IKT | 8-K | neutral | 3/10 | Inhibikase Therapeutics announced the resignation of director Dennis Berman and the appointment of Scott Wasserman, MD, | Oct 20, 2026 |
| INDP | 8-K | bearish | 6/10 | Indaptus Therapeutics completed its previously announced private placement on October 16, 2026, issuing 20,338,974 share | Oct 20, 2026 |
| LFCR | 8-K | neutral | 3/10 | Lifecore Biomedical set November 4, 2026 as the record date for a special meeting to vote on its pending merger with Haz | Oct 20, 2026 |
| AVXL | 8-K | neutral | 4/10 | Anavex announced completion of clinical conduct for two blarcamesine pharmacology studies (ADME and DDI) in healthy volu | Oct 20, 2026 |
| PURE | 8-K | bearish | 5/10 | Pure Bioscience raised $555,000 in a private placement, issuing 10,183,486 shares at $0.0545 per share to director Tom Y | Oct 20, 2026 |
| VRTX | 8-K | neutral | 2/10 | Vertex Pharmaceuticals appointed Daniel Brennan, former CFO of Boston Scientific, to its board of directors on October 2 | Oct 20, 2026 |
| TPST | 8-K | neutral | 3/10 | Tempest Therapeutics adjourned its reconvened special meeting of stockholders on October 14, 2026, because it lacked suf | Oct 20, 2026 |
| TRAX | 8-K | neutral | 2/10 | First Tracks Biotherapeutics closed a private placement of 6,106,870 shares of common stock on October 19, 2026, and ent | Oct 20, 2026 |
| PLUR | 8-K | bearish | 5/10 | Pluri Inc. issued 833,334 common shares at $1.50/share and a warrant for 833,334 shares at $1.65/share to its chairman a | Oct 20, 2026 |
| ONCY | 8-K | neutral | 3/10 | Oncolytics Biotech announced a trial-in-progress abstract and e-poster for its REO 033 study of pelareorep in RAS-mutant | Oct 20, 2026 |
| MYGN | 8-K | bullish | 7/10 | Myriad Genetics (MYGN) has entered into a definitive asset purchase agreement to sell its Prenatal Health testing busine | Oct 20, 2026 |
| RCUS | 8-K | neutral | 4/10 | Arcus Biosciences presented new clinical data from its ARC-20 platform study of casdatifan in clear cell renal cell carc | Oct 20, 2026 |
| FLNA | 8-K | bullish | 5/10 | Filana Therapeutics announced that the Fifth Circuit vacated the district court's class certification order in the secur | Oct 20, 2026 |
| PDSB | 8-K | neutral | 3/10 | PDS Biotechnology announced the resignation of four directors (Kamil Ali-Jackson, Stephen Glover, Gregory Freitag, and O | Oct 20, 2026 |
| LPCN | 8-K | neutral | 2/10 | Lipocine Inc. filed an 8-K on October 20, 2026, solely to disclose that it has updated its corporate presentation used f | Oct 20, 2026 |
| INSM | 8-K | neutral | 3/10 | Insmed appointed Paul Hudson (former CEO of Sanofi and Novartis Pharmaceuticals) and Utpal Koppikar (CFO of Verily Healt | Oct 20, 2026 |
| MBRX | 8-K | neutral | 4/10 | Moleculin Biotech filed an 8-K to announce a 1-for-20 reverse stock split, effective October 20, 2026, reducing outstand | Oct 20, 2026 |
| ODTX | 8-K | bullish | 6/10 | Odyssey Therapeutics presented completed Phase 2a induction results for OD-001, a first-in-class oral RIPK2 scaffolding | Oct 20, 2026 |
| QNRX | 8-K | bullish | 6/10 | Quoin Pharmaceuticals announced the publication of a peer-reviewed paper in Dermatology and Therapy detailing a pediatri | Oct 20, 2026 |
| RAPP | 8-K | bullish | 7/10 | Rapport Therapeutics announced positive topline Phase 2 results for RAP-219 in acute bipolar mania, meeting the primary | Oct 20, 2026 |
| BCAB | 8-K | bearish | 6/10 | BioAtla entered into a new Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $40M in common stock, repla | Oct 19, 2026 |
| ANVS | 8-K | neutral | 1/10 | Annovis Bio filed an 8-K to correct a typographical error in its June 17, 2026 proxy statement regarding audit fees. The | Oct 19, 2026 |
| CLNN | 8-K | neutral | 3/10 | Clene Inc. entered into a subaward amendment with NYU Grossman School of Medicine for the fourth year of its NIH grant, | Oct 19, 2026 |